CANY
BLUE

Caxton Associates (New York)’s bluebird bio BLUE Stock Holding History

Caxton Associates (New York)’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,619
Closed -$463K – 468
2023
Q3 		$463K Buy
7,619
+4,973
+188% +$349K 0.06% 256
2023
Q2 		$174K Buy
+2,646
New +$194K 0.03% 424
2023
Q1 		– Sell
-3,382
Closed -$468K – 502
2022
Q4 		$468K Hold
3,382
– – 0.03% 251
2022
Q3 		$428K Sell
3,382
-7,626
-69% -$863K 0.06% 270
2022
Q2 		$911K Buy
11,008
+9,339
+560% +$724K 0.09% 141
2022
Q1 		$162K Sell
1,669
-2,922
-64% -$386K 0.01% 461
2021
Q4 		$917K Buy
+4,591
New +$1.08M 0.09% 127

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Caxton Associates (New York)'s BLUE Position: Q4 2023 in Review

Caxton Associates (New York) sold out of bluebird bio (BLUE) in Q4 2023, closing a stake of 7,619 shares — an estimated $463K sold.

Caxton Associates (New York) first reported a position in BLUE in Q4 2021 and held it in 7 quarters. The position peaked at $917K in Q4 2021. 187 funds tracked by Wall St. Rank hold BLUE as of Q4 2023.

  • Caxton Associates (New York) reported no remaining bluebird bio position as of Q4 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 7,619 bluebird bio shares in Q4 2023, an estimated $463K.
  • Caxton Associates (New York) first reported a position in bluebird bio in Q4 2021 and held it in 7 quarters.
  • Caxton Associates (New York)'s bluebird bio position peaked at $917K in Q4 2021.
  • 187 funds tracked by Wall St. Rank held bluebird bio as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.